Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N Harrison1, Nicolaas Schaap2, Alessandro M Vannucchi3, Jean-Jacques Kiladjian4, Ramon V Tiu5, Pierre Zachee6, Eric Jourdan7, Elliott Winton8, Richard T Silver9, Harry C Schouten10, Francesco Passamonti11, Sonja Zweegman12, Moshe Talpaz13, Joanne Lager14, Zhenming Shun14, Ruben A Mesa15
1Guy’s and St Thomas’ NHS Foundation Trust, London, UK
2Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
3Department of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione delle Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Florence, Italy
4APHP, Hôpital Saint-Louis, INSERM, Université Paris Diderot, Centre d'Investigations Cliniques, Paris, France
5Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
6ZNA Stuivenberg Department of Hematology, Antwerp, Belgium
7Hématologie Clinique, Institut de Cancérologie du Gard, NÎMES CEDEX 9, France
8Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
9Division of Hematology/Medical Oncology, Weill Cornell Medical College, New York, NY, USA
10Division of Hematology, Department of Internal Medicine, University Hospital Maastricht, Maastricht, Netherlands
11Department of Medicine & Surgery, University of Insubria, Varese, Italy
12Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
13University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
14Sanofi Oncology, Sanofi, Cambridge, MA, USA
15Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Haematology
Tập 4
e317-e324
Thông tin tác giả